DE60233147D1 - Verwendung von hmgb1 zur aktivierung dendritischer zellen - Google Patents

Verwendung von hmgb1 zur aktivierung dendritischer zellen

Info

Publication number
DE60233147D1
DE60233147D1 DE60233147T DE60233147T DE60233147D1 DE 60233147 D1 DE60233147 D1 DE 60233147D1 DE 60233147 T DE60233147 T DE 60233147T DE 60233147 T DE60233147 T DE 60233147T DE 60233147 D1 DE60233147 D1 DE 60233147D1
Authority
DE
Germany
Prior art keywords
activation
hmgb1
dendritic cells
apc
inducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60233147T
Other languages
English (en)
Inventor
Marco Bianchi
Angelo Manfredi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SAN RAFFAELE CENTRO FOND
Fondazione Centro San Raffaele del Monte Tabor
Original Assignee
SAN RAFFAELE CENTRO FOND
Fondazione Centro San Raffaele del Monte Tabor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SAN RAFFAELE CENTRO FOND, Fondazione Centro San Raffaele del Monte Tabor filed Critical SAN RAFFAELE CENTRO FOND
Application granted granted Critical
Publication of DE60233147D1 publication Critical patent/DE60233147D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60233147T 2001-09-25 2002-09-25 Verwendung von hmgb1 zur aktivierung dendritischer zellen Expired - Lifetime DE60233147D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI001986A ITMI20011986A1 (it) 2001-09-25 2001-09-25 Metodo e composizione per l'attivazione di cellule presentanti l'antigene
PCT/IB2002/004080 WO2003026691A2 (en) 2001-09-25 2002-09-25 Use of hmgb1 for the activation of dendritic cells

Publications (1)

Publication Number Publication Date
DE60233147D1 true DE60233147D1 (de) 2009-09-10

Family

ID=11448420

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60233147T Expired - Lifetime DE60233147D1 (de) 2001-09-25 2002-09-25 Verwendung von hmgb1 zur aktivierung dendritischer zellen

Country Status (9)

Country Link
US (1) US20040242481A1 (de)
EP (1) EP1432441B1 (de)
JP (1) JP2005508913A (de)
AT (1) ATE437652T1 (de)
AU (1) AU2002341266B2 (de)
CA (1) CA2461091A1 (de)
DE (1) DE60233147D1 (de)
IT (1) ITMI20011986A1 (de)
WO (1) WO2003026691A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112121A1 (en) * 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
EP1899376A2 (de) 2005-06-16 2008-03-19 The Feinstein Institute for Medical Research Antikörper gegen hmgb 1 und fragmente davon
US7829097B2 (en) 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
US20090202500A1 (en) * 2006-10-30 2009-08-13 Genomix Co., Ltd. Pharmaceuticals That Promote Functional Regeneration of Damaged Tissues
US20100173277A1 (en) * 2007-02-15 2010-07-08 Fukuoka University Agent for Suppressing Rejection in Organ Transplantation Comprising Anti-HMGB-1 Antibody
TW200902063A (en) 2007-02-15 2009-01-16 Univ Kumamoto Therapeutic agent comprising antibody capable of specifically binding to human hmgb-1 as active ingredient
JP5241518B2 (ja) 2007-02-15 2013-07-17 国立大学法人九州大学 抗ｈｍｇｂ−１抗体を含む間質性肺疾患治療剤
CA3156538C (en) 2007-11-01 2023-12-12 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
RU2571230C2 (ru) 2008-04-30 2015-12-20 Дженомикс Ко., Лтд. Способ сбора функциональных клеток in vivo с высокой эффективностью
JP5660889B2 (ja) 2008-04-30 2015-01-28 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
BRPI0911436A2 (pt) * 2008-04-30 2016-07-12 Genomix Co Ltd vetores contendo o dna codificando as proteínas s100a8 e s100a9 e sua utilização para confecção de composições farmacêuticas para promoção da regeneração funcional de tecido lesionado
RU2599448C2 (ru) 2009-10-28 2016-10-10 Дженомикс Ко., Лтд. Средства для стимуляции регенерации тканей путем привлечения мезенхимных стволовых клеток и/или плюрипотентных стволовых клеток костного мозга в кровь
ES2643646T3 (es) 2010-01-21 2017-11-23 The Board Of Trustees Of The University Of Arkansas Vectores de vacuna y métodos para potenciar las respuestas inmunitarias
AU2011235296C1 (en) 2010-03-29 2017-05-04 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms
EP2579901B1 (de) * 2010-06-09 2019-08-07 The Board of Trustees of The University of Arkansas Impfstoff und verfahren zur linderung einer campylobacter-infektion
EP2613797B1 (de) * 2010-09-09 2015-11-04 University Of Southern California Zusammensetzungen und verfahren zur brechungsbeseitigung von biofilmen
EP2703487B1 (de) 2011-04-26 2018-06-27 Genomix Co., Ltd. Peptide zur induktion der regenerierung von gewebe und verwendung davon
WO2012170742A2 (en) * 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
MX361259B (es) 2012-10-25 2018-11-30 Univ Osaka Uso de un fragmento de peptido hmgb1 para el tratamiento del infarto al miocardio.
SG11201503215XA (en) 2012-10-25 2015-06-29 Genomix Co Ltd Novel method for treating spinal cord injury using hmgb1 fragment
NZ711019A (en) 2013-02-14 2019-07-26 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
BR112015023024B1 (pt) 2013-03-15 2022-04-19 The Board Of Trustees Of The University Of Arkansas Vetor de vacina e composições farmacêuticas compreendendo o mesmo
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
AU2016303688B2 (en) 2015-07-31 2023-06-15 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
GB201600075D0 (en) 2016-01-03 2016-02-17 Glaxosmithkline Biolog Sa Immunogenci composition
WO2017192671A1 (en) 2016-05-03 2017-11-09 The Board Of Trustees Of The University Of Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
WO2018047917A1 (ja) * 2016-09-09 2018-03-15 国立大学法人 東京大学 Ｈｍｇタンパク質と抗ｃｄ４抗体又は免疫チェックポイント制御剤との組み合わせによる相乗的抗腫瘍効果
MX2019008949A (es) 2017-01-27 2019-10-07 Stemrim Inc Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica.
CA3056088A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
JPWO2019107530A1 (ja) 2017-12-01 2020-11-26 株式会社ステムリム 炎症性腸疾患の治療薬

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214131A (en) * 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5811512A (en) * 1991-08-22 1998-09-22 The Trustees Of The University Of Pennsylvania Non-peptide peptidomimetics and related cyclic hexapeptides
US5580853A (en) * 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
FR2739292B1 (fr) * 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
IT1299583B1 (it) * 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
US6100090A (en) * 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis

Also Published As

Publication number Publication date
WO2003026691A2 (en) 2003-04-03
EP1432441B1 (de) 2009-07-29
ITMI20011986A1 (it) 2003-03-25
EP1432441A2 (de) 2004-06-30
CA2461091A1 (en) 2003-04-03
ITMI20011986A0 (it) 2001-09-25
JP2005508913A (ja) 2005-04-07
WO2003026691A3 (en) 2003-05-30
ATE437652T1 (de) 2009-08-15
AU2002341266B2 (en) 2007-11-15
US20040242481A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
DE60233147D1 (de) Verwendung von hmgb1 zur aktivierung dendritischer zellen
DE60023936D1 (de) Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen
ATE227739T1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
ATE454393T1 (de) Egvii-endoglucanase und dafür codierende nukleinsäuren
WO2003104418A3 (en) RECONSTITUTED POLYPEPTIDES
DE60238493D1 (de) Is von seltenen zellen verwendete markierte zellen
NO2011003I2 (de)
DE69932813D1 (de) Nukleinsäurebindungsproteine
DE60325892D1 (de) Stellungs- und verwendungsverfahren
ATE277198T1 (de) Verfahren zur in vitro evolution von proteinfunktionen
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DE602005017893D1 (de) Drehverfahren für silikonhydrogel-linsen
DE60128159D1 (de) Vorrichtung zur reformierung von Brennstoff
CY1118782T1 (el) Επιλογη κυτταρων που εκφραζουν ετερομερη πολυπεπτιδια
IL172729A0 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
DE60207053D1 (de) Rekombinante gelatineartige proteine zur verwendung als plasmaexpander
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
CY1109207T1 (el) Διαδικασια εχινοκανδινης
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
ATE448312T1 (de) Leitsequenzen zur verwendung bei der produktion von proteinen
ATE446314T1 (de) Methode zur reinigung von fsh
ATE457352T1 (de) Subtilisin-carlsberg-proteine mit verminderter immunogenität
DK1344827T3 (da) Frostbeskyttende proteiner fra basidiomycetes
ATE439441T1 (de) Veränderte, fluoreszierende proteine
ATE416262T1 (de) Einen grössenausschlussschritt verwendendes verbessertes bisulfit-verfahren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition